


## AD-2646

Cat. No.:	HY-124134
CAS No.:	366487-89-0
Molecular Formula:	C <sub>23</sub> H <sub>40</sub> N <sub>2</sub> O <sub>4</sub>
Molecular Weight:	408.57
Target:	Ceramidase; Caspase; PARP
Pathway:	Metabolic Enzyme/Protease; Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

**Description** AD-2646 (LCL102), a ceramide analog, can kill leukemic T cells (EC<sub>50</sub>: 40 μM). AD-2646 triggers the cleavage of caspase-8, -9 and -3, as well as the caspase substrate PARP. AD-2646 is a ceramidase inhibitor. AD-2646 induces an accumulation of endogenous ceramide owing to perturbed ceramide metabolism<sup>[1][2]</sup>.

<b>IC<sub>50</sub> &amp; Target</b>	Caspase-8	Caspase-9	Caspase 3
-------------------------------------	-----------	-----------	-----------

### REFERENCES

[1]. Granot T, et al. Caspase-dependent and -independent cell death of Jurkat human leukemia cells induced by novel synthetic ceramide analogs. *Leukemia*. 2006 Mar;20(3):392-9.

[2]. Fumiaki Tanaka, et al. In Vivo and In Vitro Inhibition of Human Cancer Cell Growth Using Adenoviral Vector Expressing FHIT Gene: Mechanism Analysis Using Microarray. *Volume 7, Issue 5, Supplement S418-S419*. May 2003.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA